Phase 1 · NCT06003465
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
A Relative Bioavailability Study to Compare the Pharmacokinetics of LY3437943 Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants
CompletedVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
- ClinicalTrials.gov ID
- NCT06003465
- Indication
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 57
- Status
- Completed
- Interventions
- Drug: LY3437943; Device: Test; Device: Reference
- Comparator
- Not reported
- Eligible ages
- 18 Years – 70 Years
- Locations
- 3 sites · United States
- Study start
- 29 Aug 2023
- Primary completion
- 8 Feb 2024
- Study completion
- 8 Feb 2024
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 29 Mar 2024
Endpoints
Primary
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943; PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of LY3437943; PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943